Alopecia Areata: looking at ferroptosis markers in blood

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will measure serum GPX4 and MDA levels in 156 participants (104 with alopecia areata, 52 healthy controls) to see if these ferroptosis biomarkers relate to disease presence and severity. The study uses ELISA assays to quantify biomarkers and compares them across acute and chronic AA subgroups while tracking SALT scores and trichoscopic findings. It is an observational study conducted at Istanbul Training and Research Hospital. Participants are adults aged 18–65, with specific exclusion criteria to limit confounding inflammatory or autoimmune conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged between 18 and 65 years.
* Formally diagnosed with Alopecia Areata based on clinical and trichoscopic examination.
* Healthy volunteers with no personal or family history of alopecia or any systemic inflammatory/autoimmune conditions (for the healthy control group).
* Patients who have provided written informed consent before any study-related procedures.

Exclusion Criteria:

* Use of topical corticosteroids, intralesional steroid injections, or topical calcineurin inhibitors within the last 1 month.
* Use of systemic immunosuppressive therapies, systemic corticosteroids, or JAK inhibitors within the last 3 months.
* Presence of any other co-existing active autoimmune or inflammatory skin diseases (e.g., Psoriasis, Vitiligo, or active autoimmune thyroiditis with elevated TSH levels).
* History of malignancy, active severe infection, chronic hepatic failure, or chronic renal failure.
* Pregnancy or lactation.
* History of heavy smoking or uncontrolled/regular use of antioxidant or vitamin supplements (e.g., Vitamin E, Vitamin C, CoQ10, NMN, resveratrol).

Where it's running

• Istanbul Training and Research Hospital, Department of Dermatology
  Istanbul, Cerrahpasa Mahallesi, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Esra Selin Kaya, MD
• Email: kayaeselin@gmail.com
• Phone: +905330257301

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cyclosporine versus methotrexate for children with alopecia areata

  This project tests whether cyclosporine or methotrexate works better as the first systemic treatment for children and teens (ages 2–17) with moderate-to-severe alopecia areata.

  Recruiting Phase 4 Erasmus Medical Center · Rotterdam · NCT07381556

• Registry for systemic treatments of alopecia areata

  This study is trying to see how well different systemic treatments work for people with moderate-to-severe alopecia areata, alopecia totalis, and alopecia universalis.

  Recruiting Erasmus Medical Center · Rotterdam · NCT06283316

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata

  This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07803874

• VC005 tablets in teens with severe alopecia areata

  This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.

  Recruiting Phase 1 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07762443

• VC005 tablets in severe alopecia areata

  This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.

  Recruiting Phase 2 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07749716

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.